Evidence map›Paper›PMID 32142726›Full record

Observational studyUrology2020

Emulating Target Clinical Trials of Radical Nephrectomy With or Without Lymph Node Dissection for Renal Cell Carcinoma.

Janine Bacic, Tao Liu, R Houston Thompson, Stephen A Boorjian, Bradley C Leibovich, Dragan Golijanin, Boris Gershman

Open access · greenAbstract readObservational Study
In one paragraph

Observational study in Urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Dissecting the role of lymphadenectomy in the management of renal cell carcinoma: past, present, and future.Kidney cancer journal : official journal of the Kidney Cancer Association · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Janine BacicAdvance-CTR, Providence, RI; Center for Evidence Synthesis in Health, School of Public Health, Brown University, Providence, RI; Lifespan Biostatistics Core, Rhode Island Hospital, Providence, RI.
Tao LiuCenter for Evidence Synthesis in Health, School of Public Health, Brown University, Providence, RI; Department of Biostatistics, School of Public Health, Brown University, Providence, RI.
R Houston ThompsonDepartment of Urology, Mayo Clinic, Rochester, MN.
Stephen A BoorjianDepartment of Urology, Mayo Clinic, Rochester, MN.
Bradley C LeibovichDepartment of Urology, Mayo Clinic, Rochester, MN.
Dragan GolijaninWarren Alpert Medical School of Brown University, Providence, RI; Division of Urology, Rhode Island Hospital, The Miriam Hospital, Providence, RI.
Boris GershmanDivision of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, MA. Electronic address: bgershma@bidmc.harvard.edu.
Mayo Clinic in Arizona · USBeth Israel Deaconess Medical Center · USBrown University · USMiriam Hospital · USRhode Island Hospital · US

Funding

Tracking and Evaluation CoreU54GM115677 · NIGMS · BROWN UNIVERSITY · PI ROUNDS, SHARON IRENE SMITH · 2016 to 2025
$45.0M
NIGMS NIH HHS U54 GM115677
6 · The paper itself

Abstract

objectiveTo emulate two target clinical trials of radical nephrectomy (RN) with lymph node dissection (LND) vs radical nephrectomy alone.

methodsUsing the National Cancer Database, we separately emulated an index trial of patients with cT1-3cN0cM0 renal cell carcinoma (RCC), designed to resemble EORTC 30881 ("index trial emulation"), and a hypothetical trial of patients at increased risk for lymph node metastases with cT1-4cN0-1cM0 RCC ("high-risk trial emulation"). A propensity score for LND was estimated using preoperative features (Model 1) or preoperative and pathologic features (Model 2). The associations of LND with overall survival (OS) were estimated using Cox regression with stabilized inverse probability weights.

resultsA total of 67,388 patients were included in the index trial emulation. Median follow-up was 49.2 (interquartile range 27.2-74.3) months. LND was not associated with improved OS when adjusting using either Model 1 (hazard ratio [HR] 1.26; 95% confidence interval [CI] 1.20-1.33; P <.0001) or Model 2 (HR 1.13; 95% CI 1.07-1.20; P <.0001). A total of 69,477 patients were included in the high-risk trial emulation. Median follow-up was 48.6 (interquartile range 26.6-73.8) months. LND was not associated with improved OS when adjusting using either Model 1 (HR 1.24; 95% CI 1.18-1.30; P <.0001) or Model 2 (HR 1.09; 95% CI 1.04-1.16; P = .001). In sensitivity analyses, LND was not associated with improved OS across cN stage, pT stage, tumor grade, histologic subtype, or probability of pN1 disease.

conclusionIn observational analyses, that emulate target trials representing EORTC 30881 and a trial of LND in high-risk RCC, LND was not associated with improved OS.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsLymphatic MetastasisLymph Node ExcisionLymph NodesNephrectomySurvival AnalysisFemaleHumansMaleMiddle AgedNeoplasm StagingPrognosisPropensity ScoreProportional Hazards ModelsRandomized Controlled Trials as Topic

Identifiers

PMID32142726
PMCPMC7255934
OpenAlexW3009584018

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.